World Pharma News Digest - 14.02.2008

AstraZeneca and Nomura Phase4 Ventures Announce Creation of New
Company "Albireo"
AstraZeneca and Nomura Phase4 Ventures today announced the signing of
a deal to form Albireo, a company focused on developing new treatments
for gastrointestinal (GI) disorders.
Read more...
* w w w .worldpharmanews . com /content/view/289/1/

The Medicines Company Reports Full Year and Fourth Quarter 2007
Financial Results
The Medicines Company (NASDAQ: MDCO) today announced its financial
results for the full year and fourth quarter of 2007. Financial
highlights for the full year of 2007:
Net revenue increased by 20% to $257.5 million for 2007 from $214.0
million for 2006.
Read more...
* w w w .worldpharmanews . com /content/view/288/1/

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Genzyme Corporation (NASDAQ: GENZ) today reported financial results
for the full year and fourth quarter of 2007 and provided an outlook
for continued strong growth in 2008 and beyond.
Read more...
* w w w .worldpharmanews . com /content/view/287/1/

Discovery of gene locus associated with cardiovascular disease raises
hope of new treatments
An international team of researchers has discovered a gene locus that
could help the development of new drugs to fight cardiovascular
disease (CVD). The locus is associated with low-density lipoprotein
(LDL) cholesterol, which plays a causal role in the development of
diseases of the cardiovascular system.
Read more...
* w w w .worldpharmanews . com /content/view/286/1/

First Head to Head Study Comparing CRESTOR(tm) and LIPITOR(R)
AstraZeneca announced the launch of a new clinical trial, SATURN,
designed to measure the impact of CRESTOR(tm) (rosuvastatin) 40 mg and
atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in
high risk patients. SATURN will compare the effects of these two
statins on the ability to decrease progression or induce regression of
atherosclerosis, the main cause of cardiovascular disease, following
two years of treatment in patients with coronary artery disease.
Read more...
* w w w .worldpharmanews . com /content/view/284/1/

Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive
Merger Agreement
Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis
Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that
they have entered into a definitive merger agreement pursuant to which
MEDRAD will acquire Possis Medical in a cash tender offer for US-
Dollar 19.50 per share, or a total equity value of approximately US-
Dollar 361 million.
Read more...
* w w w .worldpharmanews . com /content/view/285/1/

FDA Notifies Public of Adverse Reactions Linked to Botox Use
The U.S. Food and Drug Administration notified the public that Botox
and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum
toxin Type B) have been linked in some cases to adverse reactions,
including respiratory failure and death, following treatment of a
variety of conditions using a wide range of doses.
Read more...
* w w w .worldpharmanews . com /content/view/283/1/